Actuate prices 2.14M shares at $7.00 in underwritten public offering

Actuate Therapeutics (ACTU) priced an underwritten public offering of 2,142,858 shares of its common stock at an offering price of $7.00 per share of common stock. Actuate has granted the underwriters a 30-day option to purchase up to 321,428 additional shares of its common stock sold in the offering at the public offering price per share, less underwriting discounts and commissions. The offering is expected to close on September 11, 2025, subject to the satisfaction of customary closing conditions. Lucid Capital Markets is acting as sole book-running manager for the offering. Titan Partners Group, a division of American Capital Partners, is acting as financial advisor in connection with the offering. The gross proceeds to the Company from the offering are expected to be approximately $15M, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.